Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Research Briefing
  • Published:

Building a next-generation, two-component protein subunit vaccine against monkeypox virus


In this proof-of-concept study, we present a next-generation poxvirus vaccine that features a ‘two-in-one’ immunogen. Our protein vaccine construct, DAM, combines the monkeypox virus antigens A35 and M1, and was produced on the basis of structure-guided design. The DAM subunit vaccine elicited superior antiviral immunity with safety compared to cocktail vaccines or a live vaccinia virus vaccine.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Structure-based rational design of DAM demonstrated superiority in both MPXV-neutralization and in vivo protection against lethal VACV challenge.


  1. Bunge, E. M. et al. The changing epidemiology of human monkeypox-A potential threat? A systematic review. PLOS Negl. Trop. Dis. 16, e0010141 (2022). A review article on the changing epidemiology of human monkeypox.

    Article  PubMed  PubMed Central  Google Scholar 

  2. McNeil, M. M. et al. Ischemic cardiac events and other adverse events following ACAM2000® smallpox vaccine in the Vaccine Adverse Event Reporting System. Vaccine 32, 4758–4765 (2014). This article reports adverse events following smallpox vaccine vaccination.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Heraud, J. M. et al. Subunit recombinant vaccine protects against monkeypox. J. Immunol. 177, 2552–2564 (2006). This article explores potential immunogens for co-immunization-based vaccines against infections with MPXV and smallpox.

    Article  CAS  PubMed  Google Scholar 

  4. Fang, Z. et al. Polyvalent mRNA vaccination elicited potent immune response to monkeypox virus surface antigens. Cell Res. 33, 407–410 (2023). This article reports an issue of unbalanced bioavailability and immunogenicity for each component elicited by co-immunization-based vaccination strategy.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Fogg, C. N. et al. Adjuvant-enhanced antibody responses to recombinant proteins correlates with protection of mice and monkeys to orthopoxvirus challenges. Vaccine 25, 2787–2799 (2007). This article demonstrates that co-immunization with L1 and A33 effectively protects mice from lethal outcomes.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This is a summary of: Wang, H. et al. Rational design of a ‘two-in-one’ immunogen DAM drives potent immune response against monkeypox virus. Nat. Immunol. (2024).

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Building a next-generation, two-component protein subunit vaccine against monkeypox virus. Nat Immunol 25, 200–201 (2024).

Download citation

  • Published:

  • Issue Date:

  • DOI:


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing